| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8957983 | Journal of Global Antimicrobial Resistance | 2018 | 8 Pages |
Abstract
Imipenem/relebactam could provide a valuable therapeutic option in ICUs, especially against MDR isolates and those non-susceptible to other β-lactam antibiotics.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Sibylle H. Lob, Daryl J. Hoban, Katherine Young, Mary R. Motyl, Daniel F. Sahm,